J&J awaits jury verdict over Risperdal patient’s breast development

Tracy Staton

Did Johnson & Johnson hide 's potential to trigger growth in boys? Or did the drugmaker adequately disclose the potential side effect? A Philadelphia is literally out deliberating on these two questions.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS